AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02662504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic surgery Pleurectomy / extended Decortication
Description: extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
Study NCT02662504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
Study NCT00144989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide and cisplatin after chemoradiotherapy
Description: Etoposide and cisplatin after chemoradiotherapy
Study NCT00144989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and cisplatin after chemoradiotherapy
Description: Irinotecan and cisplatin after chemoradiotherapy
Study NCT03520348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-167
Description: Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic
Study NCT03520348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corneregel
Description: Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
Study NCT04291690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Component of the Intervention
Description: We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
Study NCT04291690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Component of the Intervention
Description: We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
Study NCT04291690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Component of the Intervention
Description: We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
Study NCT04291690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron-Deficiency Anemia (IDA) Component of the Intervention
Description: We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin \<130g/L in men or \<120g/L in women with (ii) a Ferritin \<100μg/L or a Ferritin \<300μg/L with a Saturation \<20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
Study NCT04367311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg
Study NCT04367311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60-75 mg/m\^2
Study NCT04367311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60-75 mg/m\^2
Study NCT04367311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m\^2
Study NCT04807088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tactile-kinesthetic Stimulation
Study NCT04807088 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05078515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PREDICT score
Description: Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
Study NCT00889603 — intervention group
Intervention type: DRUG
Intervention: Aricept® Evess
Description: 5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing).
Study NCT03628066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg by mouth daily for 24 weeks
Study NCT03628066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
Study NCT03628066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
Study NCT03628066 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oncotype DX Breast Recurrence Score
Description: Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
Study NCT04523623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen
Study NCT04523623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
Study NCT00694889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuroadaptive cognitive training
Description: Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
Study NCT03758352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (rIC)
Description: Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.
Study NCT03758352 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non remote ischemic preconditioning (non-rIC)
Description: Retrospective group who have not undergone intervention.
Study NCT03672747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct-current stimulation (tDCS)
Description: 20 minutes duration using high-definition system with center-surround configuration
Study NCT03672747 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct-current stimulation (tDCS)
Description: 20 minutes duration using high-definition system with center-surround configuration
Study NCT04236830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride/ potassium iodide
Description: Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
Study NCT04236830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
Study NCT04236830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer cement
Description: Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
Study NCT03478267 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AChE levels
Description: AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
Study NCT00563979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VitaluxPlus®
Description: 1 tablet daily
Study NCT00563979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: 1 tablet daily
Study NCT01918085 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hydrocolloid strip
Description: An adhesive strip made of hydrocolloid adhesive
Study NCT01918085 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strata strip
Description: An adhesive strip made of the Strata adhesive
Study NCT01813058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~1. placebo i.e. saline 0.9% (intravenous injection)~2. intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery.
Study NCT01813058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described.
Study NCT00675441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
Study NCT02021383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bi-weekly in person meetings with a Registered Dietician
Description: Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings.
Study NCT02021383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives for weight loss maintenance
Description: Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
Study NCT03853382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive analytic informed brief therapy
Description: The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings.
Study NCT00170768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
Study NCT00170768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
Study NCT00170768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily tablet (sham titration)
Study NCT02824770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dimming of lights and decreasing noise level
Description: The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
Study NCT02824770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine (Bustesin®) via Pain Buster ® system
Description: Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
Study NCT02824770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Bustesin®) via Pain Buster ® system
Description: Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
Study NCT02824770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl (Tramosel®) via PCA system (Gemstar®)
Description: Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
Study NCT03252834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI
Description: Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
Study NCT00467571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole, clarithromycin, amoxycillin
Description: lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
Study NCT04367636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: OCAT-sham
Description: Placebo version of the online contingent attention training preceded by psycho-education movieclip.
Study NCT04367636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: OCAT
Description: Online contingent attention training preceded by psycho-education movieclip.
Study NCT04367636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psycho-education video
Description: Both groups get to see a psycho-education video before the smartphone training starts.
Study NCT04367636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psycho-education video
Description: Both groups get to see a psycho-education video before the smartphone training starts.
Study NCT03908697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mira monitor comparison to ClearBlue monitor
Description: Testing first morning urine with hormone test sticks at home
Study NCT03405129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phoenix
Description: Phoenix cessation app
Study NCT03405129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRT order button
Description: Ability to order NRT through smartphone app
Study NCT03405129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Factoid
Description: Factoid app
Study NCT04206501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic ICD with Opti Vol-Monitor
Description: Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
Study NCT02555072 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: yellow fever vaccine
Description: yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
Study NCT04691505 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate is used as the reference group.
Study NCT04691505 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is used as the exposure group.
Study NCT02868320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS messages
Description: Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing.
Study NCT02868320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instruction booklet
Description: General detailed instructions addressing the same SMS categories.
Study NCT02868320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction booklet
Description: General detailed instructions addressing the same SMS categories.
Study NCT01580618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
Study NCT01580618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNK (Tenecteplase)
Description: Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
Study NCT02824770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl (Tramosel®) via PCA system (Gemstar®)
Description: Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
Study NCT02824770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Major abdominal surgery
Description: Any major abdominal surgery (e.g. colectomy, gastrectomy)
Study NCT02824770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Major abdominal surgery
Description: Any major abdominal surgery (e.g. colectomy, gastrectomy)
Study NCT04645654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
Study NCT00694889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer games
Description: The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
Study NCT02660294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platlet rich plasma
Description: Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
Study NCT03019835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery
Study NCT03019835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous recovery
Description: just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
Study NCT02978716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: G1T28
Study NCT02978716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study NCT02978716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study NCT01511159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data